Current stock page

Stock Analysis

AbCellera Biologics Inc. (ABCL) Stock Analysis

AbCellera Biologics Inc. (ABCL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

ABCL Stock Analysis Summary

AbCellera Biologics Inc. (ABCL) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 89/100. Risk is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

ABCL at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$11.49
AIQ Score64/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$3.65B
P/E Ratio (TTM)-23.94
Forward P/E—
EPS (Q3 FY2026)-$0.13
Revenue (Q3 FY2026)$10.64M
Dividend Yield (TTM)0.00%
Beta2.42
Volume2.68M
52-week range$2.75-$15.02
RSI 1445.24
50-Day SMA$12.34
200-Day SMA$7.24
Analyst Price Target$17.33
Next EarningsFeb 23, 2027
As of Nov 13, 2026 · Market close

ABCLAbCellera Biologics Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$11.49−$0.13 (−1.12%)

Latest quote

  • Momentum
    89
  • Value
    47
  • Quality
    61
  • Risk resilience
    34
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

ABCL Stock Analysis Summary

AbCellera Biologics Inc. (ABCL) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 89/100. Risk resilience is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, ABCL has AIQ Score of 64/100 with Momentum base of 89/100 and fading Risk resilience at 34/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (89/100) leads while Risk resilience (34/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -1.12% stock move · ABCL classified in Biotechnology.

Current Evidence

NeutralABCL is in a neutral AIQ regime; Momentum is the strongest visible factor at 89/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is ABCL Bullish or Bearish Right Now?

ABCL currently has a neutral overall setup. Momentum is the strongest factor at 89/100, while Risk Resilience is weakest at 34/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 89/100.
  • - Analyst target implies +50.86% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 47/100.
  • - Risk Resilience is weak at 34/100.
  • - Technical consensus has more sell votes than buy votes (32 vs 7).

Current Consensus

ABCL's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 7 neutral, and 32 sell votes. ABCL's 14-day RSI is 45.24, which places the stock in a neutral momentum range. ABCL's beta is 2.42, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in ABCL?

The largest recent change in ABCL is Quality moving up by 6.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+2.0
Momentum
-3.0
Quality
+6.0
Risk
+1.0

What Would Change the ABCL Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

ABCL Decision Framework

Public evidence layers, setup checks, and risk context for AbCellera Biologics Inc..

AbCellera Biologics Inc. (ABCL) Stock Analysis

AbCellera Biologics Inc. has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 89/100. Beta is 2.42, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextABCL is in a Neutral AIQ regime with score 64/100.
Signal ConflictThe primary conflict is that momentum leads at 89/100 while risk lags at 34/100.
Factor EvidenceMomentum 89/100 · Value 47/100 · Quality 61/100 · Risk 34/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 89/100.

TimingPass

Momentum is 89/100 and RSI (14) is 45.2.

Regime fitWait

ABCL is in a Neutral regime at 64/100.

Risk controlFail

Risk factor is 34/100 with beta 2.42 and annual volatility 85.28%.

ConflictWait

Current conflict: momentum leads at 89/100 while risk lags at 34/100.

AIQ Score
64/100
Price
$11.49
Beta
2.42
RSI (14)
45.2

ABCL Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

ABCL Fundamentals

ABCL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$10.64M
Net income
-$40.76M
Free cash flow
$25.3M
View full ABCL fundamental analysis

ABCL Technical Analysis

ABCL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
45.24
Price vs SMA-50
-6.86%
View full ABCL technical analysis

ABCL Stock Catalysts

Track ABCL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 23, 2027
Analyst target
$17.33
News items
5
View ABCL earnings and stock catalysts

ABCL Dividend Analysis

ABCL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View ABCL dividend history and analysis

ABCL Financial Data

ABCL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$10.64M
EPS
-$0.13
Periods
8
View ABCL financials

ABCL Risk Analysis

ABCL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
2.42
Risk score
34/100
1Y volatility
85.28%
View ABCL risk analysis

ABCL Stock News

ABCL stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read ABCL stock news

ABCL vs Biotechnology Peers

Current peer cohort: ABCL · ABSI · ABUS · ABVX · ADMA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
ABCL
Current stock
64/10047/10089/10034/1001.7385.28%Current
ABSI
Absci Corporation
53/100—85/10030/1001.58104.15%ABCL vs ABSI
ABUS
Arbutus Biopharma Corp
70/10092/10051/10062/100-0.0945.89%ABCL vs ABUS
ABVX
Abivax S.A.
35/100—34/10037/1000.2486.44%ABCL vs ABVX
ADMA
ADMA Biologics, Inc.
78/10080/10091/10056/100-0.0158.93%ABCL vs ADMA
Pairwise Compare links: ABSI · ABUS · ABVX · ADMAABCL vs ABSIABCL vs ABUSABCL vs ABVXABCL vs ADMACompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a ABCL stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for ABCL: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-23.94
As of Nov 13, 2026
Revenue growth
18.81%
Gross margin
75.57%
Current debt / equity
0.13
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$10.64M
Quarter net income
-$40.76M
Quarter free cash flow
$25.3M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
45.24
MACD
-0.14

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
34/100
Beta
2.42
Annual volatility
85.28%
Max drawdown
-40.09%

ABCL Stock FAQ

What is ABCL stock price today?

AbCellera Biologics Inc.'s current stock price is $11.49. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is ABCL bullish or bearish right now?

ABCL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is ABCL's market cap?

ABCL's market cap is $3.65B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is ABCL's current P/E ratio?

ABCL's current P/E ratio is -23.94 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is ABCL's RSI?

ABCL's 14-day RSI is 45.24 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is ABCL above its 50-day and 200-day moving averages?

ABCL is -6.86% from its 50-day SMA and 58.77% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is ABCL's next earnings date?

ABCL's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does ABCL pay a dividend?

ABCL's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.